Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-29 20:52:54 - browse：898

Drugmakers already bet big on mRNA for cancer. Now President Biden is going in, too? Anna Moneymaker/Getty Images

WASHINGTON — President Biden’s fledgling health agency, designed to accelerate under-funded research, just set its sights on one of the hottest areas of medicine — and one where the drug industry has a multibillion-dollar head start.

The White House announced Wednesday that the Advanced Research Projects Agency for Health would bankroll a $24 million project by Emory University to build messenger RNA platforms to target “cancer and other diseases,” investing in the technology behind the U.S.’s most commonly used vaccines for Covid-19.

The administration touted the news of CUREIT as the latest in Biden’s longtime mission to rein in cancer deaths, the Cancer Moonshot. But by using mRNA to treat cancer, ARPA-H is wading into a field that has advanced in fits and starts — and whose industry leaders have already spent multiples of the program’s entire budget into their own research. Moderna and BioNTech, massively profitable companies that have sold more than $80 billion worth of Covid-19 vaccines combined, have singled out oncology as the next big application for mRNA and invested accordingly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： ASCO: AstraZeneca's hat trick, and palliative care's spotlight

WSS

Industry veterans launch new biotech VC with $310M

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

KalVista pill reduced swelling 'attacks' caused by genetic disease

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

leisure time

Wikipedia

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

How digital tools helped lower hypertension in marginalized patients

What does generative AI mean for health care? We asked experts

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

23andMe had bad news about my health. I wish a person had delivered it

BMI, flaws aside, is found to be useful estimate of body fat in youth

As demand for Covid shots wanes, Moderna seeks its next success

Doctors' information doesn't help them choose wisely when sick

How one medical school became remarkably diverse

PhRMA lawsuit over Medicare drug price negotiation tossed

Wikipedia

Industry veterans launch new biotech VC with $310M

Doctors' information doesn't help them choose wisely when sick

What should King Charles tell the public about his cancer?

Intellia reports positive results for its CRISPR

Doctors' information doesn't help them choose wisely when sick

Ultragenyx gene therapy for rare liver ailment succeeds in late

hotspot

focus

focus

hotspot